The latest research study “Veterinary Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global veterinary vaccines market size reached US$ 11.12 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 19.65 Billion by 2027, exhibiting a growth rate (CAGR) of 9.60% during 2022-2027.
Veterinary vaccines refer to bio-prepared immunizations that are administered to wild species or domestic animals through parenteral and oral routes to produce protective immune responses without inducing the disease itself. They involve live attenuated, inactivated, and recombinant immunizations as some common medications. Veterinary vaccines aid in enhancing immune efficiency, reducing animal suffering, and preventing the risk of developing and transmitting various contagious zoonotic illnesses. In addition, these inoculations are reliable, cost-effective, and offer long-term prevention, owing to which they are also used to increase livestock production across the globe. Veterinary vaccines are extensively available in hospitals, clinics, pharmacies, and drug stores.
Request a free sample brochure: https://www.imarcgroup.com/veterinary-vaccines-market/requestsample
Veterinary Vaccines Market Trends and Drivers:
The escalating demand for effective immunization products and the rising prevalence of several infectious epizootic disorders are among the primary factors driving the veterinary vaccines market. Besides this, the domestication of companion and livestock animals across the globe, the enhanced focus on pet health, and the inflating number of investments in the pharmaceutical sector to improve novel injection manufacturing procedures are further augmenting the market growth. Moreover, the introduction of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) vaccines with improved efficacy, product stability, and route administration approach is also catalyzing the global market. Apart from this, the innovation of intramuscular needle-free injections and the increasing awareness among consumers toward their beneficial properties, such as enhanced safety and less pain, is acting as another significant growth-inducing factor. Additionally, the elevating need for vaccines to prevent the transmission of disease-carrying microbes from livestock-based products, including meat, leather, milk, eggs, and wool, is also stimulating the market growth. Furthermore, the expanding healthcare infrastructure and the extensive research and development (R&D) activities to enhance the efficiency of immunizations are expected to bolster the veterinary vaccines market in the coming years.
|Base Year of the Analysis||2021|
|Segment Coverage||Vaccine Type, Technology, Route of Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Incorporated, Hester Biosciences Limited, HIPRA, Indian Immunologicals Limited, Merck & Co. Inc., Neogen Corporation, Phibro Animal Health Corporation, Virbac SA and Zoetis Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499|
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Veterinary Vaccines Market Report Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Incorporated, Hester Biosciences Limited, HIPRA, Indian Immunologicals Limited, Merck & Co. Inc., Neogen Corporation, Phibro Animal Health Corporation, Virbac SA and Zoetis Inc.
The report has been segmented the market into following categories:
Breakup by Vaccine Type:
- Livestock Vaccines
- Bovine Vaccines
- Poultry Vaccines
- Porcine Vaccines
- Companion Animal Vaccines
- Canine Vaccines
- Feline Vaccines
- Equine Vaccines
Breakup by Technology:
- Attenuated Live Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
Breakup by Route of Administration:
Breakup by Distribution Channel:
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies and Drug Stores
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800